As Biden signals interest in linking drug prices with R&D costs, new study finds costs per NME are increasing
Eroom’s law (essentially the opposite of Moore’s law) holds that the development of new drugs has become slower and more expensive over time. And a new analysis, published this month in PharmacoEconomics, confirms not only that costs have gone up over the years but the difficulty in tracking how R&D has shifted.
President Joe Biden last week signaled an interest in linking drug prices to R&D costs as part of his wider pledge to bring down the cost of prescription drugs. The details of how to track such a link between R&D and price still need to be ironed out in Congress.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
